Banque Cantonale Vaudoise Increases Stock Position in AbbVie Inc. $ABBV

Key Points

• Banque Cantonale Vaudoise boosted its AbbVie stake by 24.4% in the fourth quarter, ending with 93,665 shares valued at about $21.4 million.
• AbbVie remains heavily owned by institutions, with hedge funds and asset managers holding 70.23% of the stock. Several large firms, including Vanguard, also increased their positions.
• Recent analyst sentiment is mixed but constructive: AbbVie has a Moderate Buy consensus rating and an average price target of $253.43, while the company also topped Q1 earnings estimates and continues to pay a 3.2% dividend yield.

Banque Cantonale Vaudoise increased its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 24.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 93,665 shares of the company's stock after buying an additional 18,362 shares during the period. AbbVie comprises approximately 0.8% of Banque Cantonale Vaudoise's holdings, making the stock its 20th biggest holding. Banque Cantonale Vaudoise's holdings in AbbVie were worth $21,401,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of AbbVie by 1.7% during the fourth quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company's stock worth $41,306,353,000 after acquiring an additional 3,032,438 shares during the last quarter. Legal & General Group Plc grew its stake in AbbVie by 4.3% during the 3rd quarter. Legal & General Group Plc now owns 12,004,084 shares of the company's stock valued at $2,779,426,000 after purchasing an additional 493,420 shares in the last quarter. Wellington Management Group LLP increased its holdings in AbbVie by 457.4% during the 3rd quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company's stock worth $2,439,714,000 after purchasing an additional 8,646,424 shares during the last quarter. Amundi increased its holdings in AbbVie by 15.6% during the 3rd quarter. Amundi now owns 10,508,317 shares of the company's stock worth $2,418,909,000 after purchasing an additional 1,414,621 shares during the last quarter. Finally, Ameriprise Financial Inc. raised its position in shares of AbbVie by 4.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 9,675,877 shares of the company's stock valued at $2,241,363,000 after purchasing an additional 408,426 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company's stock.

Insider Activity at AbbVie

In related news, SVP David Ryan Purdue sold 5,230 shares of the business's stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the completion of the transaction, the senior vice president owned 2,654 shares in the company, valued at $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on ABBV shares. Berenberg Bank set a $275.00 price target on shares of AbbVie in a research report on Tuesday, January 20th. Sanford C. Bernstein reiterated a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Piper Sandler boosted their target price on shares of AbbVie from $294.00 to $298.00 and gave the stock an "overweight" rating in a research report on Thursday, May 14th. Citigroup reduced their price target on shares of AbbVie from $235.00 to $230.00 and set a "neutral" rating on the stock in a research report on Tuesday, January 27th. Finally, Guggenheim reissued a "buy" rating and issued a $249.00 price objective on shares of AbbVie in a report on Friday, May 1st. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, AbbVie currently has an average rating of "Moderate Buy" and a consensus target price of $253.43.

AbbVie Stock Performance

Shares of NYSE:ABBV opened at $213.77 on Wednesday. The company's fifty day moving average is $209.49 and its two-hundred day moving average is $219.84. AbbVie Inc. has a 1-year low of $180.25 and a 1-year high of $244.81. The stock has a market capitalization of $377.69 billion, a price-to-earnings ratio of 105.31, a price-to-earnings-growth ratio of 0.72 and a beta of 0.32.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 EPS for the quarter, beating the consensus estimate of $2.59 by $0.06. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $15 billion during the quarter, compared to analyst estimates of $14.72 billion. During the same period in the previous year, the business posted $2.46 EPS. The company's quarterly revenue was up 12.4% on a year-over-year basis. Sell-side analysts expect that AbbVie Inc. will post 14.3 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a yield of 3.2%. The ex-dividend date was Wednesday, April 15th. AbbVie's payout ratio is presently 340.89%.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s neuroscience drugs boosted Q1 sales growth, with neuroscience revenue rising 26% year over year thanks to Vraylar, migraine treatments and Botox, signaling continued strength in a key growth area. Here's How Neuroscience Drugs Boost AbbVie's Q1 Sales Growth
• Positive Sentiment: AbbVie was highlighted in valuation-focused articles as potentially undervalued, which can support the stock by drawing attention to its earnings and dividend appeal. 3 Stocks That May Be Priced Below Their Estimated Value In May 2026
• Neutral Sentiment: AbbVie was listed among trending stocks after increased user interest on Zacks, but the coverage did not point to a new material catalyst by itself. Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock
• Neutral Sentiment: Evercore ISI slightly lowered its price target on AbbVie to $235 from $236, which is a small adjustment and not a major negative signal for the stock. AbbVie (ABBV) Price Target Lowered to $235 at Evercore ISI
• Negative Sentiment: Broader pharmaceutical-policy headlines about Trump’s drug-pricing push could weigh on the sector, since lower Medicare pricing would pressure pharma margins and sentiment. Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.